~~<i id='28EFB65159'><strike id='28EFB65159'><tt id='28EFB65159'><pre id='28EFB65159'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

explore

focus

author：explore 2025-10-01 02:28:19 - browse：6584

In a dark grey suit and light blue button-down shirt, Bill Sibold, CEO of Madrigal Pharmaceuticals, smiles— coverage from STAT — Madrigal CEO Bill Sibold says the company is "interested in the patients who are most in need." Madrigal Pharmaceuticals

The Food and Drug Administration is expected to approve the first medicine developed specifically to treat the serious liver disease known as MASH as soon as this week.

The pill, called resmetirom, is made by Madrigal Pharmaceuticals.

Metabolic dysfunction-associated steatohepatitis, or MASH and previously called NASH, is often associated with obesity. The accumulation of fat in the liver causes inflammation, which leads to fibrosis, or liver scarring, and can progress in more advanced stages to cirrhosis, cancer, and the need for a liver transplant.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： CDC marks new Covid

leisure time

hotspot

focus

entertainment

knowledge

LISELOTTESABROE/AFP/GettyImagesApillbeingdevelopedbyDanishdrugmakerNovoNordiskmayleadtogreaterweight

WSS

Pioneering cancer drug will cost $475,000. Analysts call it a bargain

Canadian wildfire dangers should prompt more proactive mitigation from government: Experts

Air quality improving but still lags in Black, Hispanic communities

CDC marks new Covid

How to fix the rural physician shortage in the U.S.

UnitedHealth quietly bought dozens of outpatient centers

explore

focus

leisure time

Activists slam private health insurers over coverage restrictions

First medicine developed to treat MASH expected to be approved soon

23andMe had bad news about my health. I wish a person had delivered it

Amylyx ALS drug failure raises questions and concerns

Alkermes shareholders re

Readout LOUD podcast: Venture capital turmoil, obesity drug competition

Medical leaders decry Supreme Court decision on affirmative action

Can medical device makers keep up in the race to treat obesity?

Medicare details structure of new drug price negotiation program

Headspace, Meta partner to launch VR meditation app for Quest

hotspot

A public health expert passes on football's full body collisions for youths

Amylyx ALS drug fails large clinical trial

Pioneering cancer drug will cost $475,000. Analysts call it a bargain

Readout Newsletter: Acadia, Eli Lilly, Madrigal Pharma updates

Amylyx ALS drug fails large clinical trial

Bispecific antibodies are next new thing in cancer immunotherapy

focus

entertainment

entertainment

knowledge